AT529102T - Connection to the prevention and treatment of glaucoma - Google Patents

Connection to the prevention and treatment of glaucoma

Info

Publication number
AT529102T
AT529102T AT04014078T AT04014078T AT529102T AT 529102 T AT529102 T AT 529102T AT 04014078 T AT04014078 T AT 04014078T AT 04014078 T AT04014078 T AT 04014078T AT 529102 T AT529102 T AT 529102T
Authority
AT
Austria
Prior art keywords
glaucoma
prevention
treatment
connection
Prior art date
Application number
AT04014078T
Other languages
German (de)
Inventor
Mitsuyoshi Azuma
Yukuo Yoshida
Mitsunori Waki
Masayoshi Uehata
Original Assignee
Senju Pharma Co
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP24776298 priority Critical
Priority to JP12296099 priority
Application filed by Senju Pharma Co, Mitsubishi Tanabe Pharma Corp filed Critical Senju Pharma Co
Publication of AT529102T publication Critical patent/AT529102T/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S514/00Drug, bio-affecting and body treating compositions
    • Y10S514/912Ophthalmic
    • Y10S514/913Glaucoma
AT04014078T 1998-08-17 1999-08-13 Connection to the prevention and treatment of glaucoma AT529102T (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP24776298 1998-08-17
JP12296099 1999-04-28

Publications (1)

Publication Number Publication Date
AT529102T true AT529102T (en) 2011-11-15

Family

ID=26459997

Family Applications (3)

Application Number Title Priority Date Filing Date
AT04014078T AT529102T (en) 1998-08-17 1999-08-13 Connection to the prevention and treatment of glaucoma
AT99937073T AT307609T (en) 1998-08-17 1999-08-13 Preventives / medium for glaucoma treatment
AT04014077T AT527993T (en) 1998-08-17 1999-08-13 Connection to the prevention and treatment of eye-asthenopia and pseudomyopia

Family Applications After (2)

Application Number Title Priority Date Filing Date
AT99937073T AT307609T (en) 1998-08-17 1999-08-13 Preventives / medium for glaucoma treatment
AT04014077T AT527993T (en) 1998-08-17 1999-08-13 Connection to the prevention and treatment of eye-asthenopia and pseudomyopia

Country Status (12)

Country Link
US (2) US6673812B1 (en)
EP (3) EP1459743B9 (en)
JP (2) JP3720264B2 (en)
KR (1) KR100616466B1 (en)
CN (2) CN1195547C (en)
AT (3) AT529102T (en)
AU (1) AU5198199A (en)
CA (2) CA2307285C (en)
DE (1) DE69927936T2 (en)
ES (3) ES2372572T3 (en)
HK (3) HK1069121A1 (en)
WO (1) WO2000009162A1 (en)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6699508B1 (en) * 1998-08-10 2004-03-02 Asahi Kasei Pharma Corporation Sustained release oral preparations of fasudil hydrochloride
CA2368675C (en) 1999-03-25 2008-08-12 Kunihiko Iizuka Agent for prophylaxis and treatment of interstitial pneumonia and pulmonary fibrosis
AU3328600A (en) * 1999-03-25 2000-10-16 Santen Pharmaceutical Co. Ltd. Ocular tension-lowering agents
US9603741B2 (en) 2000-05-19 2017-03-28 Michael S. Berlin Delivery system and method of use for the eye
US7829566B2 (en) 2001-09-17 2010-11-09 Werner Mederski 4-amino-quinazolines
JP2004509876A (en) 2000-09-20 2004-04-02 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトングMerck Patent Gesellschaft mit beschraenkter Haftung 4-Amino - quinazoline
US7645878B2 (en) 2002-03-22 2010-01-12 Bayer Healthcare Llc Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
CA2443918C (en) 2001-04-11 2012-06-05 Senju Pharmaceutical Co., Ltd. Visual function disorder improving agents containing rho kinase inhibitors
JP2003010158A (en) * 2001-04-26 2003-01-14 Biochemical & Pharmacological Laboratories Inc Asthenopia model, its making method, evaluating method using this model and medicine selected by using this evaluating method
ES2305435T3 (en) 2002-01-10 2008-11-01 Bayer Healthcare Ag Inhibitors rho kinase.
WO2003062225A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Pyrimidine derivatives as rho-kinase inhibitors
WO2003062227A1 (en) 2002-01-23 2003-07-31 Bayer Pharmaceuticals Corporation Rho-kinase inhibitors
GB0206860D0 (en) * 2002-03-22 2002-05-01 Glaxo Group Ltd Compounds
AU2003257588A1 (en) 2002-08-29 2004-03-19 Santen Pharmaceutical Co., Ltd. REMEDY FOR GLAUCOMA COMPRISING Rho KINASE INHIBITOR AND PROSTAGLANDINS
AU2003269413A1 (en) * 2002-11-01 2004-05-25 Pharmacia & Upjohn Company Llc Nicotinic acetylcholine agonists in the treatment of glaucoma and retinal neuropathy
JP4314433B2 (en) * 2002-11-18 2009-08-19 参天製薬株式会社 Rho kinase inhibitor and consisting of β-blockers therapeutic agent for glaucoma
US7160894B2 (en) * 2003-06-06 2007-01-09 Asahi Kasei Pharma Corporation Tricyclic compound
CN100390173C (en) 2003-06-06 2008-05-28 旭化成制药株式会社 Tricyclic compound
EP1679308B1 (en) 2003-10-15 2013-07-24 Ube Industries, Ltd. Novel indazole derivative
US8415364B2 (en) 2003-11-26 2013-04-09 Duke University Method of preventing or treating glaucoma
WO2005079829A2 (en) * 2004-02-18 2005-09-01 Wisconsin Alumni Research Foundation Method for treating glaucoma
US20050222127A1 (en) * 2004-03-30 2005-10-06 Alcon, Inc. Use of Rho kinase inhibitors in the treatment of hearing loss, tinnitus and improving body balance
FR2868310A1 (en) * 2004-04-02 2005-10-07 Oreal Topically applicable cosmetic/dermatological composition, useful for e.g. decontracting the skin, comprises a RhoA kinase production and/or activation inhibitor and an adjuvant e.g. antioxidants, fragrances and fillers
ES2553953T3 (en) * 2004-06-03 2015-12-15 Senju Pharmaceutical Co., Ltd. Drug for recovering corneal perception containing the amide compound
TWI367098B (en) 2004-12-23 2012-07-01 Kowa Co Treating agent for glaucoma
MX2007007797A (en) * 2004-12-27 2007-08-23 Alcon Inc Aminopyrazine analogs for treating glaucoma and other rho kinase-mediated diseases.
US20090029970A1 (en) * 2005-02-16 2009-01-29 Astellas Pharma Inc. Pain remedy containing rock inhibitor
EP1902731B1 (en) * 2005-06-21 2013-04-10 Kowa Company, Ltd. Preventive or remedy for glaucoma
EP1905452B1 (en) 2005-07-12 2013-06-19 Kowa Company, Ltd. Agent for prevention or treatment of glaucoma
CA2620818A1 (en) 2005-09-02 2007-03-08 Astellas Pharma Inc. Amide derivatives as rock inhibitors
US7655662B2 (en) * 2005-12-22 2010-02-02 Alcon Research, Ltd. (Indazol-5-yl)-pyrazines and (1,3-dihydro-indol-2-one)-pyrazines for treating glaucoma and controlling intraocular pressure
US7867999B1 (en) 2005-12-22 2011-01-11 Alcon Research, Ltd. Hydroxyamino- and amino-substituted pyridine analogs for treating rho kinase-mediated diseases and conditions
KR20090026264A (en) 2006-06-08 2009-03-12 산텐 세이야꾸 가부시키가이샤 Novel indazole derivative having spiro ring structure in side chain
CN101495117B (en) 2006-07-31 2012-08-15 千寿制药株式会社 Aqueous liquid preparation containing amide compound
US20100022517A1 (en) * 2006-12-18 2010-01-28 Richards Lori A Ophthalmic formulation of rho kinase inhibitor compound
AR064420A1 (en) * 2006-12-21 2009-04-01 Alcon Mfg Ltd Ophthalmic pharmaceutical compositions comprising an effective amount of 6-aminoimidazo analogs [1,2b] pyridazines, useful for treating glaucoma and / or controlling the elevated intraocular pressure or normal (iop).
KR20090096624A (en) 2006-12-26 2009-09-11 산텐 세이야꾸 가부시키가이샤 Novel n-(2-aminophenyl)benzamide derivative having an urea structure
KR20090125209A (en) 2007-03-28 2009-12-03 산텐 세이야꾸 가부시키가이샤 Ocular hypotensive agent comprising compound capable of inhibiting histon deacetylase as active ingredient
US8012972B2 (en) 2007-03-28 2011-09-06 Santen Pharmaceutical Co., Ltd. Pyridinecarboxylic acid (2-aminophenyl) amide derivative having urea structure
CN101808994B (en) 2007-07-17 2013-05-15 普莱希科公司 Compounds and methods for kinase modulation, and indications therefor
WO2009028631A1 (en) * 2007-08-29 2009-03-05 Senju Pharmaceutical Co., Ltd. Agent for promoting corneal endothelial cell adhesion
WO2009038243A1 (en) * 2007-09-21 2009-03-26 Eyegene, Inc. Composition for treating retinopathy or glaucoma comprising thrombin derived peptides
US8267882B2 (en) 2008-03-05 2012-09-18 Ivantis, Inc. Methods and apparatus for treating glaucoma
WO2009142321A1 (en) 2008-05-23 2009-11-26 参天製薬株式会社 Novel thiophenediamine derivative having urea structure
US20110130388A1 (en) * 2008-07-24 2011-06-02 Yasushi Ikuno Prophylactic or therapeutic agent for axial myopia
WO2010010715A1 (en) 2008-07-25 2010-01-28 旭化成ファーマ株式会社 Stable aqueous solution composition containing sulfonamide compound
US8273900B2 (en) 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2010032875A2 (en) * 2008-09-18 2010-03-25 Astellas Pharma Inc. Heterocyclic carboxamide compounds
US20110125090A1 (en) * 2008-11-13 2011-05-26 Peyman Gholam A Ophthalmic drug delivery system and method
US10272035B2 (en) * 2008-11-13 2019-04-30 Gholam A. Peyman Ophthalmic drug delivery method
CN105237530A (en) 2009-04-03 2016-01-13 豪夫迈罗氏公司 Propane-1-sulfonic acid {3-[5-(4-chloro-phenyl)-1H-pyrrolo[2,3-b]pyridine-3-carbonyl]-2,4-difluoro-phenyl}-amide compositions and uses thereof
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US20100298335A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and Methods for Ameliorating or Reducing Presbyopia
EP2451375B1 (en) 2009-07-09 2018-10-03 Ivantis, Inc. Single operator device for delivering an ocular implant
US8329724B2 (en) 2009-08-03 2012-12-11 Hoffmann-La Roche Inc. Process for the manufacture of pharmaceutically active compounds
WO2011021221A2 (en) 2009-08-17 2011-02-24 Reliance Life Sciences Pvt. Ltd. Compositions for spinal cord injury
ES2633317T3 (en) 2009-11-06 2017-09-20 Plexxikon, Inc. Compounds and methods for modulating kinases, and indications for it
CN103249305A (en) * 2010-07-27 2013-08-14 印斯拜尔药品股份有限公司 Method for treating ophthalmic diseases using kinase inhibitor compounds in prodrug forms
TW201906614A (en) 2011-02-04 2019-02-16 日商興和股份有限公司 Prevention or treatment of an eyedropper with glaucoma or ocular hypertension of the
ES2696023T3 (en) 2011-02-07 2019-01-11 Plexxikon Inc Compounds and methods for the modulation of kinases and indications for this
TWI558702B (en) 2011-02-21 2016-11-21 Plexxikon Inc Solid forms of a pharmaceutically active substance
US8663150B2 (en) 2011-12-19 2014-03-04 Ivantis, Inc. Delivering ocular implants into the eye
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
WO2014010654A2 (en) * 2012-07-13 2014-01-16 参天製薬株式会社 Sulfonamide compound combination
JP5557408B1 (en) 2013-04-24 2014-07-23 国立大学法人九州大学 Fundus disease treatment agent
US9844556B2 (en) 2015-03-25 2017-12-19 Megumi Honjo Preventive/therapeutic method and preventive/therapeutic agent for complications after cataract surgery
US20180296474A1 (en) 2015-10-13 2018-10-18 INSERM (Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for the treatment of retinal capillary non-perfusion
US20180369017A1 (en) * 2015-12-15 2018-12-27 Ivantis, Inc. Ocular implant and delivery system

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4838677A (en) 1987-04-06 1989-06-13 Ayetech Inc. Eye exercising devices
US5250547A (en) 1991-08-29 1993-10-05 Syntex (U.S.A.) Inc. Benzopyran derivatives
DE69231297T2 (en) 1991-09-06 2000-11-23 Yoshitomi Pharmaceutical 4-amino (alkyl) cyclohexane-1-carboxamide compounds and their use
IL104755D0 (en) 1992-02-17 1993-06-10 Ciba Geigy Ag Treatment of glaucoma
US5618955A (en) 1992-11-30 1997-04-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Fatty acid derivatives and pharmaceutical compositions containing same
IL103932A (en) 1992-11-30 1997-02-18 Yissum Res & Dev Fatty acid and pharmaceutical compositions containing them
JP3066561B2 (en) * 1993-10-07 2000-07-17 千寿製薬株式会社 Myopia prevention and treatment agent
JPH07133225A (en) 1993-11-09 1995-05-23 Dai Ichi Seiyaku Co Ltd Ciliary muscle relaxant
EP1195372A1 (en) 1994-04-18 2002-04-10 Mitsubishi Pharma Corporation N-heterocyclic substituted benzamide derivatives with antihypertensive activity
JPH08198876A (en) * 1995-01-30 1996-08-06 Yoshitomi Pharmaceut Ind Ltd A trans-n-(1h-pyrazolo(3,4-b)pyridine-4-yl)-4-guanidinomethyl cyclohexane carboxamide-1 methane sulfonic acid salt-1 hydrate
US5888173A (en) 1995-08-10 1999-03-30 Singhal; Tara Chand Health saver computer break
JP3421217B2 (en) * 1995-11-20 2003-06-30 麒麟麦酒株式会社 Rho target protein Rho kinase
US5906819A (en) 1995-11-20 1999-05-25 Kirin Beer Kabushiki Kaisha Rho target protein Rho-kinase
JPH09143099A (en) 1995-11-27 1997-06-03 Santen Pharmaceut Co Ltd Ciliary muscle tension mitigator
DE69634414D1 (en) 1995-12-21 2005-04-07 Alcon Lab Inc Use of substituted isoquinolinesulfonyl compounds for the manufacture of a medicament for the treatment of glaucoma and ocular ischemia
US5798380A (en) 1996-02-21 1998-08-25 Wisconsin Alumni Research Foundation Cytoskeletal active agents for glaucoma therapy
JPH10203982A (en) * 1996-07-05 1998-08-04 Senju Pharmaceut Co Ltd Agent for prevention and treatment of visual function disorder
CA2263425C (en) * 1996-08-12 2008-09-30 Yoshitomi Pharmaceutical Industries Ltd. Pharmaceutical agent containing rho kinase inhibitor

Also Published As

Publication number Publication date
EP1459743B1 (en) 2011-10-19
KR100616466B1 (en) 2006-08-29
US6673812B1 (en) 2004-01-06
CA2307285C (en) 2009-03-31
ES2372572T3 (en) 2012-01-23
US20030125351A1 (en) 2003-07-03
EP1034793A1 (en) 2000-09-13
JP4490748B2 (en) 2010-06-30
CN1195547C (en) 2005-04-06
CA2307285A1 (en) 2000-02-24
DE69927936D1 (en) 2005-12-01
JP3720264B2 (en) 2005-11-24
CN1494903A (en) 2004-05-12
CN1293878C (en) 2007-01-10
CA2635412C (en) 2011-06-21
EP1459743A2 (en) 2004-09-22
CN1287494A (en) 2001-03-14
JP2004277432A (en) 2004-10-07
EP1459742A3 (en) 2007-12-26
EP1459743A8 (en) 2005-02-02
HK1069120A1 (en) 2012-08-03
HK1030883A1 (en) 2006-07-14
EP1034793A4 (en) 2003-07-09
EP1459742A2 (en) 2004-09-22
AT527993T (en) 2011-10-15
ES2374518T3 (en) 2012-02-17
ES2247822T3 (en) 2006-03-01
KR20010015761A (en) 2001-02-26
AU5198199A (en) 2000-03-06
AT307609T (en) 2005-11-15
EP1459743A3 (en) 2007-12-26
EP1034793B1 (en) 2005-10-26
WO2000009162A1 (en) 2000-02-24
US6649625B2 (en) 2003-11-18
EP1459742B9 (en) 2012-05-02
CA2635412A1 (en) 2000-02-24
EP1459742B1 (en) 2011-10-12
HK1069121A1 (en) 2012-08-03
EP1459743B9 (en) 2012-08-01
DE69927936T2 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
DE69535734D1 (en) Therapeutic compositions of Venösdilatoren and Arterielldilatoren
DE69925306D1 (en) Treatment of hydrocarbon gas
DE69831567D1 (en) Device for treatment of herzarrhythien
DE60025812D1 (en) Jak-3 inhibitor for the treatment of allergic disorders
DE69434178D1 (en) R-enantiomer of N-propargyl-1-aminoindan mesylate for the treatment of various diseases and, esylate and sulfate thereof
DE69518729T2 (en) Nitric oxide-donating compound for the treatment of anal diseases
AT255539T (en) Composition for the treatment of public and industrial effluents
DE69931794D1 (en) Therapeutic compositions for treatment of mucus
DE69637316D1 (en) Prevention and treatment of cardiovascular complaints with tamoxifen-analog
DE69915087D1 (en) Treatment of textiles
DE69831134D1 (en) Treatment of water
DE69533040D1 (en) Drugs for prevention or treatment of vascular hemorrhage
DE69910803D1 (en) Fentanylzusammensetzung for treatment of acute pain
DE69939651D1 (en) Treatment of hyperproliferative diseases
AT132747T (en) Sprays for treatment of infections of the tract respiratorius
DE69500089T2 (en) Treatment of poultry
DE60132343D1 (en) Fgf-2 for treatment of diseases of the peripheral arteries
DE69841574D1 (en) Gaba analogues for the prevention and treatment of gastrointestinal complaints
DE10075033I1 (en) Substituted pyrazolyl-benzenesulfonamides for the treatment of inflammations
DE69739758D1 (en) Vaccine for the treatment of lymphoma and leukemia
DE69929060D1 (en) Beta-L-2'-deoxynucleosides for the treatment of hepatitis B virus
DE69529141D1 (en) 5-HT1F agonists for the treatment of migraine
DE69943266D1 (en) Drugs for treatment of HIV-infected mammals
AT404222T (en) Preparation for the prevention and / or treatment of vascular diseases and related secondary diseases
DE69726724D1 (en) Tetrahydropteridines and pyridylpiperazines for treatment of neurological disorders

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties